Neuraly has announced that its investigational NLY01 did not meet the primary study endpoint of improvement in motor symptoms in patients with early, untreated Parkinson’s disease.According to a company release, NLY01 is a long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor agonist. In an ongoing phase 2 trial, NLY01 did not achieve statistically significant change from
General or Local Anesthesia for DBS Surgery: Which Is Best? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.